The 'Cicada' COVID Variant (BA.3.2):
What It Is and What Nagpur Families Should Know

If you have been seeing the word “Cicada” in health news lately and wondering whether it is something to worry about, you are not alone. A new COVID-19 variant has been making headlines across the world since early 2026, and while the situation does not call for panic, it does call for awareness. Here is what is actually known, what is still uncertain, and what it means for families in Nagpur.

What Is the Cicada Variant?

The Cicada variant is the informal name for a strain of SARS-CoV-2 officially designated BA.3.2. It was first identified in South Africa in November 2024. [1] For several months after its discovery, it spread very slowly and attracted little attention. Then, in late 2025, it began gaining ground in parts of Europe, particularly in Denmark, Germany, and the Netherlands, where it eventually accounted for roughly 30 percent of COVID cases. [2] By early 2026, it had been detected in at least 23 countries and spread across 25 states in the United States through both clinical samples and wastewater surveillance. [1] [3]

The nickname “Cicada” was coined by Dr. T. Ryan Gregory, a professor of evolutionary biology at the University of Guelph in Canada, who has a history of giving variants memorable names to help the public follow their spread. [1] The name fits in a specific way: just as cicadas spend years underground before emerging in large numbers, BA.3.2 quietly existed for over a year before becoming more prominent in global surveillance data. [4]

Why Are Scientists Paying Attention to It?

The main reason BA.3.2 has drawn serious scientific attention is the sheer number of mutations in its spike protein, the part of the virus that allows it to latch onto and enter human cells. Compared to the strains used to develop the 2025-2026 COVID vaccines, namely JN.1 and its descendant LP.8.1, the Cicada variant carries approximately 70 to 75 mutations in its spike protein. [3] [4] That is a substantial divergence.

This matters because the immune defenses your body has built through vaccination or a past COVID infection are largely trained to recognize earlier versions of the spike protein. A variant with this many changes may be able to partially slip past those defenses, a property scientists call immune evasion. Laboratory studies have confirmed that BA.3.2 does show this ability to evade antibodies, which is what prompted the World Health Organization to classify it as a “variant under monitoring” in December 2025. [1] [5]

A study published in The Lancet confirmed that current COVID vaccines produce a noticeably weaker response against BA.3.2 compared to the dominant circulating strain XFG, though some level of protection against severe illness remains. [4]

Does the Cicada Variant Cause More Severe Illness?

This is the question most people are asking, and the honest answer right now is: not based on what we know so far. Multiple infectious disease experts, including Dr. William Schaffner of Vanderbilt University Medical Center and researchers at Johns Hopkins, have stated that early clinical data does not show BA.3.2 causing a distinctly more severe disease or higher mortality compared to other recent variants. [2] The symptoms reported so far are consistent with what COVID has looked like over the past couple of years: fever, cough, sore throat, fatigue, runny nose, and occasionally headache or body aches.

Dr. Donald Milton, a respiratory expert at the University of Maryland, noted that while the variant may reduce the effectiveness of current vaccines against infection, they likely still protect against severe illness. [2] That distinction matters. Protection against getting infected and protection against ending up seriously ill are two different things, and the latter is what keeps people out of hospitals.

Scientific American has reported that despite its spread, BA.3.2 currently represents fewer than 0.2 percent of sequences collected in the United States between December 2025 and February 2026, and it has not been linked to any overall increase in COVID hospitalizations. [3]

What Are the Symptoms to Watch For?

Based on current evidence, the symptoms of BA.3.2 infection are not distinctly different from other COVID variants or from common respiratory illnesses like the flu and the cold. The CDC lists the following as common COVID-19 symptoms in 2026: fever or chills, cough, sore throat, runny or stuffy nose, body aches, headache, fatigue, shortness of breath, and loss of taste or smell in some cases. [1]

Because these symptoms overlap heavily with influenza and other respiratory viruses currently circulating, testing remains the only reliable way to distinguish between them. This is important because COVID is still treated with specific antiviral medications like Paxlovid, which work best when started early. Experts at Johns Hopkins have confirmed that existing COVID antiviral drugs remain effective against BA.3.2, which is a significant reassurance. [1]

How Worried Should You Be?

Cautious, not panicked, is the appropriate response. Several public health experts have been consistent on this point. Neil Maniar, director of the public health program at Northeastern University, described the situation well: at this stage, COVID is part of daily life in a way similar to the flu, and the focus should be on protecting higher-risk individuals rather than treating every new variant as a crisis. [4]

Those at higher risk include older adults, people with uncontrolled diabetes or high blood pressure, those with heart or lung conditions, cancer patients, and anyone on immunosuppressant medication. For these groups, the emergence of a variant with immune-evasive properties warrants extra care. [4]

For healthy adults and children with no underlying conditions, the risk profile from BA.3.2 as currently understood is not dramatically different from other recent variants. [5]

What About India and Nagpur?

As of the time of writing, BA.3.2 has been detected in 23 countries, primarily in Europe and North America. [3] [4] There are no confirmed reports of widespread community circulation in India yet, but the pattern of how COVID variants travel globally means it is a matter of monitoring rather than assuming immunity. International travel, particularly from Europe, remains the most likely pathway for introduction.

India’s population carries a complex mix of immunity from past infections across multiple waves and vaccination coverage that varies by region and age group. How BA.3.2 behaves in this immune landscape will become clearer as surveillance data from the subcontinent accumulates.

Nagpur families who have elderly relatives, family members with chronic conditions like diabetes or heart disease, or anyone who has not received a COVID vaccine dose in the past year should take this as a timely reason to revisit their vaccination status and consult their doctor.

What Can You Do Right Now?

The protective measures that have worked through every COVID variant continue to apply. If you have not received the available COVID vaccine, getting it still provides meaningful protection against severe illness even against immune-evasive variants. [2] Frequent handwashing, staying home when unwell, and wearing a mask in crowded or poorly ventilated spaces are straightforward steps that reduce transmission of not just COVID but influenza and other respiratory viruses as well. [4]

If you or a family member develops respiratory symptoms, getting tested early allows for timely treatment if needed. Do not dismiss symptoms as “just a cold” if you or someone in your home is in a higher-risk category.

The Bigger Picture

The Cicada variant is a reminder that SARS-CoV-2 continues to evolve, and that monitoring it is a permanent feature of global public health. What has changed since 2020 is that our tools for tracking, diagnosing, and treating COVID are far better than they were. Wastewater surveillance, rapid genomic sequencing, broadly effective antivirals, and vaccines that still protect against severe outcomes even when their protection against infection weakens, are all meaningful advantages. [3]

The goal for families is informed awareness without unnecessary anxiety. Stay updated through credible sources, keep your vaccinations current, and if you have any concerns about your specific health situation, speak to a doctor. The science on BA.3.2 is still developing, and recommendations may evolve as more clinical data comes in.

At Alright Hospital, our internal medicine and general physician teams are available for consultations if you have concerns about COVID symptoms or want to assess your vaccination needs. Both our Jafar Nagar and Lashkaribagh branches offer outpatient care and diagnostic support.

Sources and References

[1] TODAY.com — “A New, Highly Mutated COVID Variant Called ‘Cicada’ Is Spreading in the US. Know These Symptoms” (Updated March 31, 2026) https://www.today.com/health/coronavirus/new-covid-variant-ba32-cicada-symptoms-2026-rcna265088

[2] PBS NewsHour — “What we know about the new ‘Cicada’ COVID-19 variant” https://www.pbs.org/newshour/health/what-we-know-about-the-new-cicada-covid-19-variant

[3] Scientific American — “New ‘Cicada’ COVID Variant Is Spreading in the U.S. — Here’s What to Know” https://www.scientificamerican.com/article/new-cicada-covid-variant-is-spreading-in-the-u-s-heres-what-to-know/

[4] Northeastern University News — “What You Need to Know About the New ‘Cicada’ COVID-19 Variant” (March 27, 2026) https://news.northeastern.edu/2026/03/27/new-covid-19-cicada-variant/

[5] Michigan Public Radio — “New COVID variant ‘Cicada’ detected in Michigan: What to know” (March 30, 2026) https://www.michiganpublic.org/health/2026-03-30/new-covid-variant-cicada-detected-in-michigan-what-to-know